Cover Image
Market Research Report

Psoriatic Arthritis Global Clinical Trials Review, H1, 2018

Published by GlobalData Product code 226840
Published Content info 251 Pages
Delivery time: 1-2 business days
Price
Back to Top
Psoriatic Arthritis Global Clinical Trials Review, H1, 2018
Published: June 29, 2018 Content info: 251 Pages
Description

GlobalData's clinical trial report, "Psoriatic Arthritis Global Clinical Trials Review, H1, 2018" provides an overview of Psoriatic Arthritis clinical trials scenario. This report provides top line data relating to the clinical trials on Psoriatic Arthritis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents
Product Code: GDHC5049CTIDB

Table of Contents

Table of Contents 2

  • List of Tables 4
  • List of Figures 5
  • Report Guidance 6
  • GlobalData Clinical Trials Report Coverage 7
  • Clinical Trials by Region 8
  • Clinical Trials and Average Enrollment by Country 9
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
  • Top Five Countries Contributing to Clinical Trials in Europe 12
  • Top Countries Contributing to Clinical Trials in North America 13
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa 14
  • Top Five Countries Contributing to Clinical Trials in Central and South America 15
  • Clinical Trials by G7 Countries: Proportion of Psoriatic Arthritis to Musculoskeletal Disorders Clinical Trials 16
  • Clinical Trials by Phase in G7 Countries 17
  • Clinical Trials in G7 Countries by Trial Status 18
  • Clinical Trials by E7 Countries: Proportion of Psoriatic Arthritis to Musculoskeletal Disorders Clinical Trials 19
  • Clinical Trials by Phase in E7 Countries 20
  • Clinical Trials in E7 Countries by Trial Status 21
  • Clinical Trials by Phase 22
  • In Progress Trials by Phase 23
  • Clinical Trials by Trial Status 24
  • Clinical Trials by End Point Status 25
  • Subjects Recruited Over a Period of Time 26
  • Clinical Trials by Sponsor Type 27
  • Prominent Sponsors 28
  • Top Companies Participating in Psoriatic Arthritis Therapeutics Clinical Trials 29
  • Prominent Drugs 30
  • Latest Clinical Trials News on Psoriatic Arthritis 31
  • Jun 13, 2018: Celgene data underscore meaningful clinical benefits of OTEZLA (apremilast) on key domains of psoriatic arthritis 31
  • Jun 11, 2018: Lilly to Unveil New Data on Taltz at the EULAR 2018, Furthering Commitment to Scientific Discovery in Immunology 31
  • Jun 04, 2018: TREMFYA (guselkumab) Study Indicating The Significance Of Inhibiting IL-23 Pathway In Adults With Psoriatic Arthritis Published In The Lancet 32
  • May 30, 2018: Gilead and Galapagos Announce Results With Filgotinib in the Phase 2 Equator Study in Psoriatic Arthritis and Progression Into Phase 3 for the Selection Study in Ulcerative Colitis 33
  • Apr 03, 2018: New publication on Cimzia (certolizumab pegol) shows psoriatic arthritis patients achieved robust treatment targets and sustained improvements across multiple disease domains 34
  • Clinical Trial Profile Snapshots 35

Appendix 249

  • Abbreviations 249
  • Definitions 249
  • Research Methodology 250
  • Secondary Research 250
  • About GlobalData 251
  • Contact Us 251
  • Source 251

List of Tables

  • Psoriatic Arthritis Therapeutics, Global, Clinical Trials by Region, 2018* 8
  • Psoriatic Arthritis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 9
  • Psoriatic Arthritis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 10
  • Psoriatic Arthritis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2018* 11
  • Psoriatic Arthritis Therapeutics Clinical Trials, Europe, Top Five Countries, 2018* 12
  • Psoriatic Arthritis Therapeutics Clinical Trials, North America, Top Countries, 2018* 13
  • Psoriatic Arthritis Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2018* 14
  • Psoriatic Arthritis Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2018* 15
  • Proportion of Psoriatic Arthritis to Musculoskeletal Disorders Clinical Trials, G7 Countries (%), 2018* 16
  • Psoriatic Arthritis Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 17
  • Psoriatic Arthritis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 18
  • Proportion of Psoriatic Arthritis to Musculoskeletal Disorders Clinical Trials, E7 Countries (%), 2018* 19
  • Psoriatic Arthritis Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 20
  • Psoriatic Arthritis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 21
  • Psoriatic Arthritis Therapeutics, Global, Clinical Trials by Phase, 2018* 22
  • Psoriatic Arthritis Therapeutics, Global, Clinical Trials In Progress by Phase 2018* 23
  • Psoriatic Arthritis Therapeutics, Global, Clinical Trials by Trial Status, 2018* 24
  • Psoriatic Arthritis Therapeutics Clinical Trials, Global, by End Point Status, 2018* 25
  • Psoriatic Arthritis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 26
  • Psoriatic Arthritis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2018* 27
  • Psoriatic Arthritis Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 28
  • Psoriatic Arthritis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 29
  • Psoriatic Arthritis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 30

List of Figures

  • Psoriatic Arthritis Therapeutics, Global, Clinical Trials by Region (%), 2018* 8
  • Psoriatic Arthritis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 9
  • Psoriatic Arthritis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 10
  • Psoriatic Arthritis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2018* 11
  • Psoriatic Arthritis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2018* 12
  • Psoriatic Arthritis Therapeutics Clinical Trials, North America, Top Countries (%), 2018* 13
  • Psoriatic Arthritis Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2018* 14
  • Psoriatic Arthritis Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2018* 15
  • Proportion of Psoriatic Arthritis to Musculoskeletal Disorders Clinical Trials, G7 Countries (%), 2018* 16
  • Psoriatic Arthritis Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 17
  • Psoriatic Arthritis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 18
  • Proportion of Psoriatic Arthritis to Musculoskeletal Disorders Clinical Trials, E7 Countries (%), 2018* 19
  • Psoriatic Arthritis Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 20
  • Psoriatic Arthritis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 21
  • Psoriatic Arthritis Therapeutics, Global, Clinical Trials by Phase (%), 2018* 22
  • Psoriatic Arthritis Therapeutics, Global, Clinical Trials In Progress by Phase, 2018* 23
  • Psoriatic Arthritis Therapeutics, Global, Clinical Trials by Trial Status, 2018* 24
  • Psoriatic Arthritis Therapeutics Clinical Trials, Global, by End Point Status, 2018* 25
  • Psoriatic Arthritis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 26
  • Psoriatic Arthritis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2018* 27
  • Psoriatic Arthritis Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 28
  • Psoriatic Arthritis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 29
  • Psoriatic Arthritis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 30
  • GlobalData Methodology 250
Back to Top